Disease · MONDO_0002571
Comparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 13 of 13
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Chemotherapy vs Chemotherapy + Low-Dose WBRT: deaths from any cause | 3 of 44 | 1 of 43 | 87 | NCT01399372 | Trial comparisons |
| Chemotherapy vs Chemotherapy + Low-Dose WBRT: serious adverse events | 22 of 43 | 21 of 43 | 86 | NCT01399372 | Trial comparisons |
| MATRIX - R-ICE - Conditioning and ASCT vs Enrolled, But Not Treated: deaths from any cause | 50 of 75 | 1 of 4 | 79 | NCT02329080 | Trial comparisons |
| MATRIX - R-ICE - Conditioning and ASCT vs Enrolled, But Not Treated: serious adverse events | 46 of 75 | 0 of 4 | 79 | NCT02329080 | Trial comparisons |
| PCNSL Cohort Nivolumab 240 mg (Q2W) vs PTL Cohort Nivolumab 240 mg (Q2W): deaths from any cause | 32 of 47 | 13 of 19 | 66 | NCT02857426 | Trial comparisons |
| PCNSL Cohort Nivolumab 240 mg (Q2W) vs PTL Cohort Nivolumab 240 mg (Q2W): serious adverse events | 33 of 47 | 15 of 19 | 66 | NCT02857426 | Trial comparisons |
Lenalidomide+Nivolumab Followed by Venetoclax, Ibrutinib,Prednisone, Obinutuzumab, Lenalidomide-Nivo vs Cohort 1, Arm 2: Experimental- VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide): deaths from any cause | 2 of 4 | 6 of 10 | 14 | NCT05211336 | Trial comparisons |
Lenalidomide+Nivolumab Followed by Venetoclax, Ibrutinib,Prednisone, Obinutuzumab, Lenalidomide-Nivo vs Cohort 1, Arm 2: Experimental- VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide): Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0). | 4 of 4 | 9 of 10 | 14 | NCT05211336 | Trial comparisons |
Lenalidomide+Nivolumab Followed by Venetoclax, Ibrutinib,Prednisone, Obinutuzumab, Lenalidomide-Nivo vs Cohort 1, Arm 2: Experimental- VIPOR (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, Lenalidomide): serious adverse events | 3 of 4 | 6 of 10 | 14 | NCT05211336 | Trial comparisons |
| Phase I: Temozolomide 100mg vs Phase I: Temozolomide150 mg: Number of Phase I Participants Experiencing Toxicity | 1 of 6 | 3 of 6 | 12 | NCT00068250 | Trial comparisons |
Cohort 1 Gray-Zone Lymphoma (GZL) vs Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL): Number of Participants With Serious and/or Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0). | 2 of 2 | 9 of 9 | 11 | NCT03255018 | Trial comparisons |
| Cohort 1 Gray-Zone Lymphoma (GZL) vs Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL): deaths from any cause | 0 of 2 | 5 of 9 | 11 | NCT03255018 | Trial comparisons |
| Cohort 1 Gray-Zone Lymphoma (GZL) vs Cohort 2 Extra-nodal Diffuse Large B-cell Lymphoma (DLBCL): serious adverse events | 0 of 2 | 5 of 9 | 11 | NCT03255018 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002571/comparisons